Topic Archives: Abbvie (ABBV)

The Manchurian Candida

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and biography here.] “Many things you hear in this room are untrue.” (sign posted in Yale-New Haven Medical Center physician cafeteria) […]

The Long Case for Receptos

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]

Jimmy Mengel’s “Delta-9” — is it “One Drug to End All Pain — Naturally?”

“The Greatest Medical Breakthrough in 72 Years… “One Drug to End All Pain — Naturally “A new revolutionary drug called ‘Delta-9’ will send a small group of companies skyrocketing for life-altering gains… starting December 31, 2014. “The last time something like this happened 72 years ago… investors had the opportunity to turn every $1,000 into […]

Hepatitis with a C

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • Avatar

    Travis ---you're right on-----The five he talks about are: ABBV, PFE, JNJ, MRK amd UNH...

  • Avatar

    ABBV has been in a down trend channel since 26 jan 2018...

  • Avatar

    Although this investment letter has done well in the past, since late 2018 it has been the fastest way to lose money I'v...

  • Avatar

    ABBV has been a very good stock over the past 1.5 years. One subscription service said to sell when it fell a month or t...

  • RampageKy

    Must be Abbvie (ABBV). They want to tender $7.5B worth of their own stock. Sure makes me curious about buying, although ...

  • SoGiAm

    AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment Today 8:12 AM ET (MarketWatch) Sh...

  • SoGiAm

    $ENTA $ABBV MAVIRET™ (glecaprevir/pibrentasvir) Is Now Available in Japan for the Treatment of Chronic Hepatitis C Acr...

  • Avatar

    $AUPH. He made millions in Pharmacyclics (PCYC) which was sold to Abbvie (ABBV). Two or three years ago my first (very...

  • Avatar

    $ABBV $GILD $AMGN - An interesting article from IBD evaluating comparatively three biotech giants "AbbVie Stronger B...

  • Avatar

    $RGLS (long) http://tinyurl.com/z6qeum9 AbbVie ($ABBV) is touting impressive cure rates for its new daily hep C combo...

  • Avatar

    GILD's HEP C scripts latest data. Gilead Sciences: Does Anyone Care About Hep-C Anymore? By Ben Leviso...

  • Avatar

    Got this teaser for a prescription buy to Money Map Press.It was easy to figure out the company.It is Orasure Technologi...

  • Avatar

    I started watching Mike Ward's pitch this afternoon and decided I could dope this out on my own. I spent 6 hours learnin...

  • Avatar

    The following is an excerpt from a piece on GILD: "A group of developers are racing ahead in the clinic with new hep C ...

  • karmaswimswami

    Readers here who might be more comfortable with a blue-chip rather than a speculative pick might really want to take a l...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch